Expertise in
24
conditions

Dr. Haider S. Mahdi

Obstetrics and Gynecology | Oncology
University Of Pittsburgh Physicians
300 Halket St, Suite 1750, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Expertise in
24
conditions
University Of Pittsburgh Physicians
300 Halket St, Suite 1750, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Haider Mahdi is an Obstetrics and Gynecologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Mahdi is highly rated in 24 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Mahdi is currently accepting new patients.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MI
Hospital Affiliations
Henry Ford Health Wyandotte Hospital
Beaumont Hospital - Dearborn
Huron Valley-Sinai Hospital
Henry Ford Health West Bloomfield Hospital
Mercy Health Saint Mary's
Languages Spoken
English
Arabic
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Suite 1750, Pittsburgh, PA 15213
Other Locations
ADVANTAGE HEALTH/SAINT MARY'S MEDICAL GROUP
250 Cherry St Se, Grand Rapids, MI 49503

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: BET Bromodomain Inhibitor ZEN-3694, Ipilimumab, Nivolumab
Study Phase: Phase 1
Phase Ll Study of a BET Inhibitor, ZEN003694, Combined with a PARP Inhibitor, Talazoparib, in Patients with Recurrent Ovarian Cancer
Phase Ll Study of a BET Inhibitor, ZEN003694, Combined with a PARP Inhibitor, Talazoparib, in Patients with Recurrent Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: ZEN003694, Talazoparib
Study Phase: Phase 2
The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study
The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study
Enrollment Status: Recruiting
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, E7777
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2025
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: July 12, 2023
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tisotumab vedotin
Study Phase: Phase 2
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial
Enrollment Status: Withdrawn
Publish Date: February 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

99 Total Publications

All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
Journal: Gynecologic oncology
Published: January 21, 2025
Similar Doctors
Expertise in
44
conditions
Dr. Melissa Burgess
Oncology | Hematology
Expertise in
44
conditions
Dr. Melissa Burgess
Oncology | Hematology

University Of Pittsburgh Physicians

200 Lothrop St, 
Pittsburgh, PA 
 (0.4 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Burgess is an Oncologist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Burgess is highly rated in 44 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Merkel Cell Carcinoma, Liposarcoma, and Gamma Knife Radiosurgery.

Adam M. Brufsky
Expertise in
20
conditions
Dr. Adam M. Brufsky
Oncology | Hematology Oncology
Expertise in
20
conditions
Dr. Adam M. Brufsky
Oncology | Hematology Oncology

University Of Pittsburgh Physicians

5230 Centre Ave, 
Pittsburgh, PA 
 (1.6 mi)
412-623-2047
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Brufsky is an Oncologist and a Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Brufsky is highly rated in 20 conditions, according to our data. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy.

Liza C. Villaruz
Expertise in
14
conditions
Dr. Liza C. Villaruz
Oncology | Hematology Oncology
Expertise in
14
conditions
Dr. Liza C. Villaruz
Oncology | Hematology Oncology

University Of Pittsburgh Physicians

5230 Centre Ave, 
Pittsburgh, PA 
 (1.6 mi)
412-623-2047
Languages Spoken:
English
See accepted insurances

Liza Villaruz is an Oncologist and a Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Villaruz is highly rated in 14 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mahdi's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 13 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile